Charles Garvin

CEO

Mr. Garvin, a seasoned CEO and technology investor, has a BA and JD from Harvard University, and did PhD study at Oxford University as a Rhodes Scholar. He has been Chairman, CEO, or controlling shareholder at a number of tech and biotech companies during a 35-year career. Mr. Garvin served as an officer and member of the Board of Directors at the Boston Consulting Group, a leading strategy consulting organization, and was one of the original principals of the Beta Group, a seed capital firm which has incubated several successful medical technology companies. Subsequently Mr. Garvin has served as Chairman or represented controlling interests in companies of up to $350 million in revenues, including TVC Communications, Riviera Trading, EK Holdings and Basic Industries. He is currently a Director of Tosk, Inc. (cancer chemotherapies) and Senior Advisor to SanBio (stem cell therapies).

Dr. George Martin

President

Dr. Martin is among the nation’s most distinguished scientists in areas addressed by Riptide, including fibrosis and inflammation; and is also a seasoned biotech executive. Most recently, Dr. Martin served as Senior Vice President / R&D and the second employee of Fibrogen, where he built the technical team and initiated two programs that have each attracted $300 million-plus corporate partnerships, and are in Phase II and Phase III clinical trials. Fibrogen became a public company in late 2014. Previously, Dr. Martin occupied positions of progressively increasing responsibility in a 25-year career at the National Institutes of Health, culminating as Scientific Director of the National Institute on Aging, and head of the NIH Gerontology Research Center, managing several hundred researchers. His personal scientific achievements include the invention of Matrigel, licensed to Corning, for which it is an important product and nearly universal cell culture medium in labs worldwide.

Dr. Jesse Jaynes

Executive Vice President – Drug Design

Dr. Jaynes is a leading biochemist specializing in peptide design, and has served as Chief Scientific Officer at two previous companies. As documented in >120 peer-reviewed publications and >60 patents, the Jaynes Lab was first in the world to demonstrate antiprotozoal¹, plant disease resistance², and anticancer³ activity for designed lytic peptides both in vitro and in vivo. In agriculture, Dr. Jaynes' antimicrobial peptides have been licensed by US Sugar / Tropicana for use in citrus crop protection.

1. See e.g. Jaynes et.al., FASEB 2(13): 2878-2883; Arrowood, Jaynes et.al., Antimicrobial Agents and Chemotherapy, 35(2): 224-2272.
2. See e.g. Jaynes et.al., BioEssays 6(6): 263; Jaynes et.al., Plant Science 89: 43-53.
3. See e.g. Jaynes et.al., Peptide Research 2(2): 157-169; Yates, Jaynes et.al., Biochemical Pharmacology 81: 104-111.

Dr. L. Edward Clemens

Principal Scientist

Dr. Clemens is a biologist and pharmacologist with 35 years' experience in drug development, including the first identification of antagonists useful for controlling estrogen-dependent cancers. Dr. Clemens has led research teams at companies including Parke-Davis, Scios, and Metabolex, including the team that prepared data for the IND and ultimate approval of a recombinant form of human natriuretic peptide for congestive heart failure.

Dr. Clayton Yates

Principal Scientist

Dr. Yates, Professor of Oncology, Pathology and Urology at Johns Hopkins University, has administered numerous grant awards from the National Cancer Institute and the Congressionally Directed Medical Research Program at the Department of Defense, and is a frequent invited speaker at national and international conferences focusing on prostate and breast cancer. Dr. Yates' research focuses on how the tumor microenvironment influences epigenetic regulators, which can cause tumor cells to undergo epithelial to mesenchymal transition (EMT), and promote metastasis.